Amgen Inc.
-4.11 %
-12.16 %
Yet to be announced
Company Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Revenue Sources
PassAfter reviewing Amgen's financial statements and business operations, no significant revenue is derived from prohibited sources. The company's primary revenue streams come from the development and sale of biotechnology medicines and therapeutic treatments, which are permissible activities in Islamic finance.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $8.15b | $7.69b | - | $723.0m | 0.00% | 9.40% |
| Dec. 31, 2024 | $9.09b | $7.52b | - | $747.0m | 0.00% | 9.93% |
| Sept. 30, 2024 | $8.5b | $7.23b | - | $776.0m | 0.00% | 10.73% |
| June 30, 2024 | $8.39b | $7.29b | - | $808.0m | 0.00% | 11.09% |
Based on the financial data provided for the last four quarters: Interest expense to total expense ratios ranged between 10-11% of total expenses across all quarters, which is significantly above the 5% threshold considered acceptable in Islamic finance principles.
Operational Ethics
PassAmgen maintains manufacturing facilities and research centers in various countries. However, there is no evidence of significant ongoing relationships with entities involved in human rights violations. The company's operations appear to be conducted in compliance with international human rights standards.
Comments